322 patients were randomly assigned to receive placebo ( 55 patients ) or SYR-472 at 125 mg ( 54 patients ) , 25 mg ( 52 patients ) , 50 mg ( 51 patients ) , 100 mg ( 55 patients ) or 200 mg ( 55 patients ) .